Health Care Sector in Focus: Complementary Research on Great Basin, PhotoMedex, Intellipharmaceutics, Transenterix, and Medovex
NEW YORK, April 30, 2015 /PRNewswire/ --
Editor Note: For more information about this release, please scroll to bottom.
Moments ago, Analysts Review released new research updates concerning several important developing situations including Great Basin Scientific, Inc. (NASDAQ: GBSN), PhotoMedex, Inc. (NASDAQ: PHMD), Intellipharmaceutics International Inc. (NASDAQ: IPCI), Transenterix Inc (NYSE: TRXC), and Medovex Corp. (NASDAQ: MDVX). Analysts Review provides a single unified platform for investors' to hear about what matters - proudly employing registered CFA® research staff and rigorous compliance procedures. The full research reports are being made available to the public for informational purposes only.
To access our full PDF reports on a complementary basis, please visit the links below.
--
Today's update concerns the following companies:
============
Full PDF Download Links (you may have to copy and paste the following links into your browser):
GBSN Research Report: ( http://get.analystsreview.com/pdf/?c=Great%20Basin%20Scientific&d=30-Apr-2015&s=GBSN ),
PHMD Research Report: ( http://get.analystsreview.com/pdf/?c=PhotoMedex%20Inc&d=30-Apr-2015&s=PHMD ),
IPCI Research Report: ( http://get.analystsreview.com/pdf/?c=Intellipharmaceutics%20International&d=30-Apr-2015&s=IPCI ),
TRXC Research Report: ( http://get.analystsreview.com/pdf/?c=Transenterix%20Inc&d=30-Apr-2015&s=TRXC ),
MDVX Research Report: ( http://get.analystsreview.com/pdf/?c=Medovex%20Corp.&d=30-Apr-2015&s=MDVX ).
============
--
Analyst Update: Distribution Agreement, Financial and Operating Results, Upcoming Results, and Device Testing
Reviewed by: Rohit Tuli, CFA®
U.S. stocks fell on Wednesday as disappointing US economic data weighed on investor sentiment. The NASDAQ Composite slipped 0.63% to 5,023.64, the Dow Jones Industrial Average lost 0.41%, to close at 18,035.53, and the S&P 500 ended the session at 2,106.85, down 0.37%. European stocks stumbled on Wednesday caused by a sharp surge in the value of the euro against US dollar. Germany's DAX 30, witnessed the biggest point decline since October 2008, down 378.94 points, or 3.21%. Also, France's CAC 40, and London's FTSE 100 dropped 2.6% and 1.2%, respectively on Wednesday. Meanwhile, Asian markets mostly closed lower on Wednesday. Australia's S&P ASX and Hong Kong's Hang Seng index both slipped on Wednesday, while the Shanghai Composite Index saw modest gains. The Nikkei was closed on Wednesday due to the annual Showa Day holiday.
Great Basin Scientific (Great Basin), a molecular diagnostics company, on April 13, 2015, announced continued strong growth in the number of customers using its sample-to-result molecular diagnostic technology during the first quarter of 2015.
PhotoMedex, on April 7, 2015 announced the signing of an exclusive distribution agreement by its subsidiary, Radiancy Inc., with Synergy Trading Corporation for certain no!no!™ products in Japan. The agreement includes Radiancy's no!no! 8800 and no!no! PRO.
On April 14, 2015, Intellipharmaceutics reported its first quarter 2015 financial results (three months ended February 28, 2015). The Company recorded a net loss of $0.9 million or $0.04 per diluted common share for the reported period, compared with a net income of $2.2 million or $0.09 per common share during the same period previous year, attributed to lower licensing revenues compared to the prior period.
TransEnterix, a medical device company, on April 22, 2015, announced that it plans to release first quarter 2015 financial and operating results before the market opens on Wednesday, May 6, 2015. Todd M. Pope, President and CEO, and Joseph P. Slattery, Executive Vice President and Chief Financial Officer, will host a conference call to discuss these results starting at 8:30 am ET the same day.
Medovex, a developer of medical technology products, on April 2, 2015, announced that its DenerveX™ device has successfully completed its Phase III design and development device testing.
--
About Analysts Review
At Analysts Review, we provide our members with a simple and reliable way to leverage our economy of scale. Most investors do not have time to track all publicly traded companies, much less perform an in-depth review and analysis of the complexities contained in each situation. That's where Analysts Review comes in. We provide a single unified platform for investors' to hear about what matters. Situation alerts, moving events, and upcoming opportunities.
Analysts Review was designed for investors. By providing the best information available, we have set ourselves apart as one of the premier online investor communities.
--
Editor Note: This is not company news. We are an independent source and our views do not reflect the companies mentioned.
Compliance Procedure: Content is researched, written and reviewed on a best-effort basis. This document, article or report is prepared and authored by Analysts Review, represented by Rohit Tuli, CFA®. An outsourced research services provider has only reviewed the information provided by Analysts Review in this article or report according to the procedures outlined by Analysts Review. Analysts Review is not entitled to veto or interfere in the application of such procedures by the outsourced provider to the articles, documents or reports, as the case may be.
Further Resources: For more information about this release including editorial notes, compliance procedures and legal disclosures, please visit: http://www.analystsreview.com/editors
CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.
SOURCE Analysts Review
WANT YOUR COMPANY'S NEWS FEATURED ON PRNEWSWIRE.COM?
Newsrooms &
Influencers
Digital Media
Outlets
Journalists
Opted In
Share this article